Holen Sie sich die Stockscreener-App
3.23
5.56%
-0.19
Handel nachbörslich:
3.39
0.16
+4.95%
Schlusskurs vom Vortag:
$3.42
Offen:
$3.44
24-Stunden-Volumen:
663.14K
Relative Volume:
1.71
Marktkapitalisierung:
$346.51M
Einnahmen:
$45.44M
Nettoeinkommen (Verlust:
$-35.43M
KGV:
-10.09
EPS:
-0.32
Netto-Cashflow:
$-25.39M
1W Leistung:
-9.78%
1M Leistung:
-14.32%
6M Leistung:
-30.84%
1J Leistung:
-22.17%
1-Tages-Spanne:
$3.215
$3.45
1-Wochen-Bereich:
$3.215
$3.64
52-Wochen-Spanne:
$3.215
$5.545
Maxcyte Inc Stock (MXCT) Company Profile
Firmenname
Maxcyte Inc
Sektor
Branche
Telefon
301-517-5556
Adresse
9713 KEY WEST AVENUE,, ROCKVILLE
Vergleichen Sie MXCT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| MXCT | 3.23 | 346.51M | 45.44M | -35.43M | -25.39M | -0.32 |
| ABT | 117.36 | 202.64B | 41.22B | 5.77B | 6.49B | 2.94 |
| SYK | 389.40 | 150.72B | 21.97B | 3.59B | 3.21B | 6.74 |
| BSX | 90.45 | 133.82B | 15.91B | 1.79B | 1.89B | 0.82 |
| MDT | 87.59 | 112.98B | 32.58B | 3.93B | 5.15B | 2.71 |
| EW | 69.89 | 40.52B | 6.60B | 4.16B | 490.10M | 2.34 |
Maxcyte Inc Stock (MXCT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-11-29 | Eingeleitet | Craig Hallum | Buy |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-08-24 | Eingeleitet | BTIG Research | Buy |
| 2021-08-24 | Eingeleitet | Cowen | Outperform |
| 2021-08-24 | Eingeleitet | Stephens | Overweight |
| 2021-08-24 | Eingeleitet | Stifel | Buy |
| 2021-08-24 | Eingeleitet | Wedbush | Outperform |
| 2021-08-24 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Maxcyte Inc Aktie (MXCT) Neueste Nachrichten
MaxCyte stock touches 52-week low at $3.23 amid market challenges - Investing.com
Will MaxCyte's Q2 Results Surpass Market Expectations? - RTTNews
CADIAN CAPITAL MANAGEMENT, LP Expands Stake in MaxCyte Inc - GuruFocus.com
MaxCyte celebrates 25 years of innovation driving cell engineering-based therapeutics - News-Medical.Net
MaxCyte Celebrates 25 Years - Baystreet.ca
MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics - The Manila Times
MaxCyte Marks 25 Years of Innovation with Groundbreaking Cell Therapy Breakthrough | MXCT Stock News - StockTitan
MaxCyte stock touches 52-week low at $3.27 amid market shifts - Investing.com Canada
MaxCyte stock touches 52-week low at $3.27 amid market shifts By Investing.com - Investing.com South Africa
500: Something went wrong - Investing.com
FY2024 Earnings Estimate for MaxCyte Issued By William Blair - MarketBeat
MaxCyte, Inc. (NASDAQ:MXCT) Q3 2024 Earnings Call Transcript - MSN
MaxCyte, Inc. (MXCT) Reports Q3 Loss, Tops Revenue Estimates - MSN
MaxCyte Files Quarterly Report, Highlights Financial Progress - TipRanks
MaxCyte’s Revenue Grows and Strategic Moves Unveiled - TipRanks
Investors ignore increasing losses at MaxCyte (LON:MXCT) as stock jumps 10% this past week - Simply Wall St
MaxCyte, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Constellation Energy Corp (CEG-Q) QuotePress Release - The Globe and Mail
MaxCyte Director Sells Shares Amid Active Trading - TipRanks
Goldman Sachs Group (GS-N) QuotePress Release - The Globe and Mail
MaxCyte Expands Stock Capital with New Issuance - TipRanks
MaxCyte (LON:MXCT) Stock Passes Below 50 Day Moving AverageTime to Sell? - MarketBeat
MaxCyte to Participate in Two Upcoming Investor Conferences - StockTitan
MaxCyte to Join Key Investor Conferences in November - TipRanks
MaxCyte’s Insider Stock Activity in Focus - TipRanks
MaxCyte director Johnston sells $11,166 in stock - Investing.com
Overcome the limitations of conventional transfection with MaxCyte Electroporation - LabRoots
MaxCyte, Inc. (LON:MXCT) is largely controlled by institutional shareholders who own 65% of the company - Yahoo Finance
MaxCyte (MXCT) to Release Quarterly Earnings on Wednesday - MarketBeat
Grant of Options and Restricted Stock Units - ShareCast
MaxCyte Awards Stock Options to Boost Growth - TipRanks
MaxCyte (MXCT) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Finance
MaxCyte Appoints Cynthia Collins to its Board of Directors - ForexTV.com
MaxCyte Strengthens Board with Cynthia Collins Appointment - TipRanks
MaxCyte appoints Ali Soleymannezhad as Chief Commercial Officer - Head Topics
MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024 - ForexTV.com
MaxCyte to Unveil Q3 2024 Financial Results - TipRanks
People on the Move: Ali Soleymannezhad, Chief Commercial Officer, MaxCyte - BioBuzz
MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer - citybiz
MaxCyte appoints new chief commercial officer - ShareCast
MaxCyte appoints Soleymannezhad as CCO - TipRanks
MaxCyte Names New CCO for Market Expansion - TipRanks
MaxCyte upgraded to Buy from Hold at Deutsche Bank - TipRanks
Marshall Wace LLP Acquires New Holdings in MaxCyte, Inc. (NASDAQ:MXCT) - MarketBeat
Maxcyte: Reaching Financial Inflection With CASGEVY Ramp Up (NASDAQ:MXCT) - Seeking Alpha
Stan Erck Sells 47,689 Shares of MaxCyte, Inc. (LON:MXCT) Stock - MarketBeat
MaxCyte, Inc. (LON:MXCT) Insider Sells £185,033.32 in Stock - Defense World
MaxCyte Director Executes Stock Options Sale - TipRanks
MaxCyte director Stanley Erck sells shares worth over $178k - Investing.com
MaxCyte director Stanley Erck sells shares worth over $178k By Investing.com - Investing.com Australia
MaxCyte, Inc. (NASDAQ:MXCT) Director Sells $80,161.97 in Stock - MarketBeat
Finanzdaten der Maxcyte Inc-Aktie (MXCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.38%
0.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):